Recombinant human endostatin

N/A

Report date: 2025/05/15 20:00:08

Base Information

Drug NameRecombinant human endostatin
Drug Alias Name重组人内皮抑素Endostatin
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor receptor antagonists
TargetsVascular endothelial growth factor receptor
Therapy Area/IndicationsSkin MelanomaCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBoston Children'S Hospital
China Registration ClassN/A

Develop Information

Active CompaniesFudan University
Inactive CompaniesShanghai Jiao Tong University School of MedicineShandong Xiansheng Zaiming Biopharmaceutical Co LtdZhejiang University
Active IndicationsSkin MelanomaMelanoma
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksWikipedia